Global Hemophilia Drugs Industrial and Market studies 2016-2020
"Global
Hemophilia Drugs Market 2016-2020"
The Report covers current Market Trends, Analysis, Forecast, Review,
Share, Size, Growth, Effect.
Description-
About
Hemophilia
Hemophilia
is an X-linked genetic disorder that results in excessive blood loss
during an injury, causing fatigue or even death. The disorder is more
common in males and affects roughly 400,000 people globally every
year. Hemophilia A is the more common form of this disorder, while
hemophilia B is the rare form of hemophilia. To mitigate this
disorder, plasma-derived clotting factors or recombinant clotting
factors have been developed and are administered to the affected
individual. The therapy is usually done in two ways: short acting
therapeutic and long-acting therapeutic.
Technavios
analysts forecast the global hemophilia drugs market to grow at a
CAGR of 4.76% during the period 2016-2020.
Covered
in this report
The
report covers the present scenario and the growth prospects of the
global hemophilia drugs market for 2016-2020. To calculate the market
size, the report considers the revenue generated from the sales of of
drugs used for the treatment of hemophilia, including hemophilia A,
hemophilia B, and inhibitors.
The
market is divided into the following segments based on geography:
Americas
APAC
EMEA
Technavio's
report, Global Hemophilia Drugs Market 2016-2020, has been prepared
based on an in-depth market analysis with inputs from industry
experts. The report covers the market landscape and its growth
prospects over the coming years. The report also includes a
discussion of the key vendors operating in this market.
Key
vendors
Baxalta
Bayer
CSL
Behring
Novo
Nordisk
Pfizer
Other
prominent vendors
Alnylam
Pharmaceuticals
Amarna
Therapeutics
Asklepios
BioPharmaceutical
Biogen
BioMarin
Catalyst
Bioscience
Chiesi
Farmaceutici
Dimension
Therapeutics
Emergent
BioSolutions
F.
Hoffmann-La Roche
Grifols,
Kedrion Biopharma
Octapharma
rEVO
Biologics
OPKO
Biologics
Sangamo
Biosciences
Spark
Therapeutics
Swedish
Orphan Biovitrum
UniQure
Biopharma.
Market
driver
Focus
on prophylactic treatment
For
a full, detailed list, view our report
Market
challenge
Low
diagnosis rate
For
a full, detailed list, view our report
Market
trend
Increase
in technological innovations
For
a full, detailed list, view our report
Key
questions answered in this report
What
will the market size be in 2020 and what will the growth rate be?
What
are the key market trends?
What
is driving this market?
What
are the challenges to market growth?
Who
are the key vendors in this market space?
Comments
Post a Comment